Drug slows Alzheimer’s but can it make a real difference? – CTV

Nov. 30, 2022

An experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening, researchers reported Tuesday – but it remains unclear how much difference that might make in people’s lives.

Japanese drugmaker Eisai and its U.S. partner Biogen had announced earlier this fall that the drug lecanemab appeared to work, a badly needed bright spot after repeated disappointments in the quest for better Alzheimer’s treatments.

Now the companies are providing full results of the study of nearly 1,800 people in the earliest stages of the mind-robbing disease. The data was presented at an Alzheimer’s meeting in San Francisco and published in The New England Journal of Medicine. U.S. regulators could approve the drug as soon as January.

Every two weeks for 18 months, study participants received intravenous lecanemab or a dummy infusion. Researchers tracked them using an 18-point scale that measures cognitive and functional ability.

Read more: https://www.ctvnews.ca/health/drug-slows-alzheimer-s-but-can-it-make-a-real-difference-1.6174260

NationTalk Partners & Sponsors Learn More